Trials / Completed
CompletedNCT03874780
Vibe First In Human Study for the Assessment of Safety and Initial Performance of the Vibe Delivery System in Subjects With Idiopathic Overactive Bladder
First in Human (FIH) Study for the Evaluation of the Safety and Early Performance of the Vibe Delivery System for the Delivery of Botox™ in Subjects With Idiopathic Overactive Bladder (OAB)
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 10 (actual)
- Sponsor
- Vensica Therapeutics Ltd. · Industry
- Sex
- Female
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
This First In Human study is aimed to evaluate the safety and initial efficacy of the Vibe delivery system in delivering Botox (TM) to the bladder wall in patients diagnosed with overactive bladder.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DEVICE | Vibe Delivery system | delivery of Botox (TM) to the bladder wall using an ultrasound technology with the Vibe delivery system |
Timeline
- Start date
- 2019-01-29
- Primary completion
- 2019-03-31
- Completion
- 2019-03-31
- First posted
- 2019-03-14
- Last updated
- 2019-12-05
Locations
2 sites across 2 countries: Czechia, Portugal
Source: ClinicalTrials.gov record NCT03874780. Inclusion in this directory is not an endorsement.